VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Sunday morning. The brokerage issued a sell rating on the stock.

Separately, Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, August 16th.

VolitionRx Stock Performance

Shares of VolitionRx stock opened at $0.60 on Friday. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.23. The stock has a market cap of $54.86 million, a PE ratio of -1.49 and a beta of 1.09. The firm has a 50-day moving average of $0.68 and a 200-day moving average of $0.69.

VolitionRx (NYSE:VNRX) last announced its earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.34 million. Equities research analysts predict that VolitionRx will post -0.31 earnings per share for the current fiscal year.

Insider Activity

In other VolitionRx news, Director Guy Archibald Innes bought 150,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was purchased at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the completion of the purchase, the director now directly owns 406,683 shares of the company’s stock, valued at approximately $272,477.61. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC grew its stake in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.